IMM01, our Core Product, is a next-generation CD47-targeted molecule. It is the first SIRPα-Fc fusion protein to enter into the clinical stage in China. IMM01 designed with IgG1 Fc can fully activate macrophages via a dual mechanism — simultaneously blocking the “don't eat me” signal by disrupting CD47/SIRPα interaction and delivering the “eat me” signal through the engagement of activating Fcγ receptors on macrophages. Furthermore, the CD47-binding domain of IMM01 was specifically engineered to avoid human red blood cell (RBC) binding. With the differentiated molecule design, IMM01 has achieved a favorable safety profile and demonstrated its ability to potently activate macrophages.
Our Key Products include IMM0306 (CD47×CD20), IMM2902 (CD47×HER2) and IMM2520(CD47×PD-L1), which are CD47-based bispecific molecules sharing a common structure: connecting the same engineered CD47-binding domain used in IMM01 to a base antibody with antibody-dependent cellular cytotoxicity (ADCC)-enhanced human IgG1 Fc fragment. This unique structural design with the engineered CD47-binding fragment allows our CD47-based bispecific molecules to avoid RBC binding, thus enabling the adoption of an ADCC-enhanced IgG1 Fc fragment capable of inducing full macrophage activation and much improved antibody-dependent cellular phagocytosis (ADCP) and ADCC activity, which results in stronger antitumor immune responses compared to most IgG4-based CD47 bispecific antibodies.
Compared to combination therapies against the same targets, our bispecific molecules are more likely to bind with two targets co-expressed on the same cancer cell, which is the prerequisite for the dual-targeting strategy to show synergistic effects. As demonstrated in our preclinical studies, our bispecific molecules can exert more potent antitumor activity than the combination therapies with same targets even at a relatively lower dose level. In addition, the symmetric structure of our bispecific molecules developed on our mAb-Trap platform minimizes mismatch during the production process, allowing for ease of manufacturing, product stability, higher titer and protein yield.